Real-World Study Illuminates Waldenstrom Macroglobulinemia Outcomes

Real-World Study Illuminates Waldenstrom Macroglobulinemia Outcomes

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted precision medicine strategies.

Iopofosine-131 Earns FDA Breakthrough for Waldenstrom Macroglobulinemia

Iopofosine-131 received FDA breakthrough status for relapsed or refractory Waldenstrom macroglobulinemia, showing strong response rates in early trials.

FDA grants breakthrough therapy status for Cellectar’s iopofosine I 131

The designation is granted to iopofosine I 131 for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM), a subtype of lymphoplasmacytic lymphoma currently without a cure. WM remains The post FDA grants breakthrough therapy status for Cellectar’s iopofosine I 131 appeared first on Pharmaceutical Business review.